Talkmed Group Ltd
SGX:5G3
Intrinsic Value
TalkMed Group Ltd. is an investment holding company, which engages in the provision of medical oncology, stem cell transplants, and palliative care services. [ Read More ]
The intrinsic value of one 5G3 stock under the Base Case scenario is 0.344 SGD. Compared to the current market price of 0.415 SGD, Talkmed Group Ltd is Overvalued by 17%.
Valuation Backtest
Talkmed Group Ltd
Run backtest to discover the historical profit from buying and selling 5G3 stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Talkmed Group Ltd
Current Assets | 103.1m |
Cash & Short-Term Investments | 89.9m |
Receivables | 11.4m |
Other Current Assets | 1.8m |
Non-Current Assets | 12.7m |
Long-Term Investments | 2.8m |
PP&E | 9.7m |
Other Non-Current Assets | 222k |
Current Liabilities | 27.3m |
Accounts Payable | 3.8m |
Other Current Liabilities | 23.5m |
Non-Current Liabilities | -1.6m |
Long-Term Debt | 4.5m |
Other Non-Current Liabilities | -6.1m |
Earnings Waterfall
Talkmed Group Ltd
Revenue
|
83.8m
SGD
|
Operating Expenses
|
-44.8m
SGD
|
Operating Income
|
39m
SGD
|
Other Expenses
|
-6.9m
SGD
|
Net Income
|
32.2m
SGD
|
Free Cash Flow Analysis
Talkmed Group Ltd
5G3 Profitability Score
Profitability Due Diligence
Talkmed Group Ltd's profitability score is 80/100. The higher the profitability score, the more profitable the company is.
Score
Talkmed Group Ltd's profitability score is 80/100. The higher the profitability score, the more profitable the company is.
5G3 Solvency Score
Solvency Due Diligence
Talkmed Group Ltd's solvency score is 99/100. The higher the solvency score, the more solvent the company is.
Score
Talkmed Group Ltd's solvency score is 99/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
5G3 Price Targets Summary
Talkmed Group Ltd
According to Wall Street analysts, the average 1-year price target for 5G3 is 0.66 SGD .
Shareholder Return
5G3 Price
Talkmed Group Ltd
Average Annual Return | -1.4% |
Standard Deviation of Annual Returns | 9.32% |
Max Drawdown | -29% |
Market Capitalization | 550.1m SGD |
Shares Outstanding | 1 326 660 000 |
Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
TalkMed Group Ltd. is an investment holding company, which engages in the provision of medical oncology, stem cell transplants, and palliative care services. The firm is a provider of medical oncology and palliative care health care services in Singapore. The firm operates through two segments: Oncology services, and Cellular and gene therapy related products and services. The Oncology services provide specialist doctors and clinical staff to Parkway Cancer Centre (PCC), a division of Parkway Hospitals Singapore Pte. Ltd. for the provision of specialist medical oncology services (consultancy services). The company also provides consultancy services to Thu Cuc International General Hospital (TCH), to enable TCH to operate a medical center for the provision of oncology services in Hanoi, Vietnam. The company also provides consultancy services to the patients in Beijing and Chongqing. Cellular and gene therapy-related products and services include the provision of goods and services related to cellular and gene therapy through its subsidiary, CellVec Pte. Ltd. (CellVec).
Contact
IPO
Employees
Officers
The intrinsic value of one 5G3 stock under the Base Case scenario is 0.344 SGD.
Compared to the current market price of 0.415 SGD, Talkmed Group Ltd is Overvalued by 17%.